New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.

Alzheimer’s Association International Conference 2016, Toronto, Canada

Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling

View Poster

Share this: